Spero Therapeutics Inc.

0.7542

+0.01421.92%

Post-market: 0.75420.00000.00%17:33 EDT

Volume:35.94K

Turnover:27.62K

Market Cap:42.16M

PE:-0.59

High:0.7860

Open:0.7400

Low:0.7400

Close:0.7400

Loading ...

Overview Company News Filings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPRO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"SPRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","market":"US","secType":"STK","nameCN":"Spero Therapeutics Inc.","latestPrice":0.7542,"timestamp":1744920000000,"preClose":0.74,"halted":0,"volume":35943,"hourTrading":{"tag":"盘后","latestPrice":0.7542,"preClose":0.7542,"latestTime":"17:33 EDT","volume":4,"amount":2.94,"timestamp":1744925595236},"delay":0,"floatShares":41896552,"shares":55900641,"eps":-1.27,"marketStatus":"Market Closed","change":0.0142,"latestTime":"04-17 16:00:00 EDT","open":0.74,"high":0.786,"low":0.74,"amount":27620.7074598,"amplitude":0.062162,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.27,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1509595200000,"exchange":"NASDAQ","adjPreClose":0.74,"postHourTrading":{"tag":"盘后","latestPrice":0.7542,"preClose":0.7542,"latestTime":"17:33 EDT","volume":4,"amount":2.94,"timestamp":1744925595236},"volumeRatio":0.16367411811174443,"impliedVol":0.0019,"impliedVolPercentile":0.3227},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPRO\",,,,,undefined,":{"symbol":"SPRO","floatShares":41896552,"roa":"-30.93%","roe":"-89.62%","lyrEps":-1.268849,"volumeRatio":0.16367411811174443,"shares":55900641,"dividePrice":0.06,"high":0.786,"amplitude":0.062162,"preClose":0.74,"low":0.74,"week52Low":0.5052,"pbRate":"0.91","psRate":"0.88","week52High":1.72,"institutionHeld":0.1648,"latestPrice":0.7542,"eps":-1.27,"divideRate":0.079554,"volume":35943,"delay":0,"ttmEps":-1.27,"open":0.74,"prevYearClose":1.03,"prevWeekClose":0.6,"prevMonthClose":0.72,"prevQuarterClose":0.72,"fiveDayClose":0.5775,"twentyDayClose":0.7776,"sixtyDayClose":0.874},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPRO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492612453","title":"EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2492612453","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492612453?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:43","pubTimestamp":1734363780,"startTime":"0","endTime":"0","summary":"Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an extensive search to yield a commercial partner. The company is already facing a massive cash crunch and without a partner, it is unable to sustain the development cost of reni-cel. The candidate was evaluated in a phase I/II/III RUBY study and a phase I/II EdiTHAL study for severe sickle cell disease  and transfusion-dependent beta thalassemia , respectively.Per Editas, it plans to work closely with the clinical study sites, regulators and other parties to determine the path forward for patients enrolled in the RUBY and EdiTHAL studies. The abandonment of these studies has significantly delayed the company’s hopes of earning any revenues.Additionally, the biology of HBG1/2 has been validated in clinical settings, such as the RUBY study with reni-cel, further supporting its potential. Beyond HSCs, E","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/edit-stock-falls-decision-end-154300702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CTMX","EDIT","SPRO","BK4556","BK4196","SCD","CSTL"],"gpt_icon":0},{"id":"2492961989","title":"ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2492961989","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492961989?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:42","pubTimestamp":1734360120,"startTime":"0","endTime":"0","summary":"AbbVieABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.Nimble’s lead preclinical asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and inflammatory bowel disease . Per AbbVie, IL23R is a validated therapeutic target in certain autoimmune diseases, significantly contributing to psoriasis and IBD by driving inflammation and enhancing immune responses.In the past three months, shares of AbbVie have lost 10.4% compared with the industry’s 14.4% decline.Skyrizi and Rinvoq are expected to collecti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0004445239.USD","LU0158827948.USD","LU1061106388.HKD","BK4196","SPRO","CTMX","LU0795875086.SGD","LU1057294990.SGD","LU1496350171.SGD","LU0912757837.SGD","LU0738911758.USD","LENZ","LU1291159041.SGD","IBD","LU1037948541.HKD","ABBV","LU1839511570.USD","LU0256863902.USD","CSTL","IE0009355771.USD","LU0820561818.USD","LU1244550494.USD","IE00BVYPNV92.GBP","LU0456855351.SGD","LU1718418525.SGD","IE00BDGV0183.EUR","LU2237443622.USD","IE00B42XCP33.USD","LU0203347892.USD","IE00BSNM7G36.USD","LU0661504455.SGD","LU0170899867.USD","SG9999011175.SGD","LU2237443978.SGD","LU0965509101.SGD","BK4566","LU0882574055.USD","LU0122379950.USD","BK4588","LU1267930573.SGD","LU2237443382.USD","LU2089284900.SGD","LU0689472784.USD","LU0256863811.USD","LU2089283258.USD","LU2023251221.USD","LU0965509283.SGD","LU2237443549.SGD","SG9999015978.USD","LU1551013342.USD"],"gpt_icon":0},{"id":"2491930999","title":"KRYS Stock Down on Initial Clinical Updates on KB407 & KB408","url":"https://stock-news.laohu8.com/highlight/detail?id=2491930999","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491930999?lang=en_us&edition=fundamental","pubTime":"2024-12-14 00:08","pubTimestamp":1734106080,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.KB407 is being developed in a phase I study for the treatment of cystic fibrosis , while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency .The latest clinical updates include molecular data as well as safety and tolerability data for both KB407 and KB408.Year to date, shares of Krystal Biotech have rallied 39.8% against the industry’s decline of 8.7%.The open-label, phase I CORAL-1 study is evaluating KB407 for treating adult patients with CF. The company recently activated two additional clinical sites for its KB407 phase I CORAL-1 study.Per the company, the CORAL-1 study is designed to include up to three dose escalation cohorts evalua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-stock-down-initial-clinical-160800239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KRYS","BK4196","BK4588","BK4093","CSTL","CTMX","CF","SPRO","BK4585","BK4139"],"gpt_icon":0},{"id":"2491305286","title":"SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS","url":"https://stock-news.laohu8.com/highlight/detail?id=2491305286","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491305286?lang=en_us&edition=fundamental","pubTime":"2024-12-13 23:58","pubTimestamp":1734105480,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary progressive multiple sclerosis .The FDA grants breakthrough therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that the therapy may provide substantial improvements over available treatments.There are no approved therapies to treat nrSPMS at present. Multiple sclerosis  is a chronic neurodegenerative disease that causes disability accumulation over time, which is not properly addressed by the currently available therapies, and there remains a significant unmet need for MS treatment.Year to date, shares of Sanofi have declined 5.5% against the industry’s increase of 7.4%.Breakthrough Therapy Tag Based on Data From SNY's HERCULES Study. The FDA’s Breakthrough Therapy designation for tolebrutinib was bas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MPLv._QOfr9ekgf5qyZbUA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MPLv._QOfr9ekgf5qyZbUA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4c89fa4c828d913dc49739912177a966"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snys-tolebrutinib-gets-fda-breakthrough-155800256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225283273.USD","CSTL","BK4516","LU2089283258.USD","MG","LU1162221912.USD","CTMX","BK4196","BK4139","IE00B7SZL793.SGD","LU1074936037.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","LU1989772923.USD","BK4123","LU0267386448.USD","IE00BFXG1179.USD","CDP","BK4223","LU0314104364.USD","IE00B66KJ199.SGD","BK4581","BK4007","LU0158827781.USD","LU2271345857.HKD","LU2089284900.SGD","IE0031619046.USD","LU0158827948.USD","BK4534","LU0106261372.USD","LU1720051017.SGD","BK4585","LU0320765646.SGD","LU1720051108.HKD","LU0006306889.USD","BK4127","LU2028103732.USD","SNY","LU1548497426.USD","SPRO","LU1363072403.SGD","IE00BZ1G4Q59.USD","LU2357305700.SGD","LU0971096721.USD","LU2111349929.HKD","BK4504","LU0098860793.USD","LU0106831901.USD","IE00B19Z4B17.USD","BK4588"],"gpt_icon":0},{"id":"2491537299","title":"NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD","url":"https://stock-news.laohu8.com/highlight/detail?id=2491537299","media":"Zacks","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491537299?lang=en_us&edition=fundamental","pubTime":"2024-12-13 21:48","pubTimestamp":1734097680,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  has adopted a positive opinion recommending the label expansion of Ozempic  to treat patients with type II diabetes  and chronic kidney disease  in the EU. Subject to approval, the drug will be indicated as an adjunct to the standard of care for the prevention of the progression of renal impairment in T2D and CKD patients. A final decision from EMA is expected soon.Please note that Novo Nordisk’s once-weekly subcutaneous diabetes injection, Ozempic, is already approved in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses for treating T2D mellitus in adults, adjunct to diet and exercise. Ozempic is also approved for reducing the risk of major adverse cardiovascular events in adults with T2D mellitus and established cardiovascular disease.The recommendation from the CHMP was based on positive results from Novo Nordisk’s FLOW outcomes study, which achieved its primary endpoint of a supe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-gets-positive-chmp-opinion-134800017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","BK4585","BK4007","CHMP","LU1093756168.USD","CSTL","LU0154236417.USD","IE00BKVL7J92.USD","BK4139","NVO","BK4156","BK4588","SPRO","CTMX","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK4532","BK4087"],"gpt_icon":0},{"id":"2491377703","title":"Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2491377703","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491377703?lang=en_us&edition=fundamental","pubTime":"2024-12-13 00:00","pubTimestamp":1734019200,"startTime":"0","endTime":"0","summary":"Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies evaluating its investigational drug bempikibart one in atopic dermatitis  and the other in alopecia areata .While data from the AA study showed promising clinical activity for the drug, the study did not meet its primary endpoint in part B of the eczema study.Based on the above results, management has decided to proceed with developing the drug for AA, but will no longer pursue development in the eczema indication.Following the news, shares of Q32 Bio hit an all-time low of $5.80. The latest announcement did not impress investors, who raised concerns about the drug’s efficacy. Wall Street analysts were also not impressed with the results, one even calling it ‘messy.’。Year to date, Q32 Bio’s shares have lost 45.6% compared with the industry’s 8.7% decline.In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 58 cents per share to earnings","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-q32-bio-stock-160000430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AA","QTTB","BK4196","BK4139","CSTL","BK4585","SPRO","BK4153","CTMX","BK4588"],"gpt_icon":0},{"id":"2491336030","title":"CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2491336030","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491336030?lang=en_us&edition=fundamental","pubTime":"2024-12-12 23:21","pubTimestamp":1734016860,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant, for treating patients with amyotrophic lateral sclerosis , a degenerative neurologic disorder.The double-blind, placebo-controlled DAZALS study evaluated two doses of dazucorilant  for treating patients with ALS.The study did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised  in patients treated with dazucorilant versus those treated with placebo.Shares of Corcept were down in pre-market trading on Dec. 12 following the announcement of the news on Dec. 11.Year to date, shares of Corcept have rallied 85% against the industry’s decline of 4.6%.Data from the study showed that patients who were treated with dazucorilant experienced substantially more gastrointestinal upset compared to those who received placebo at the onset of treatment.Upon completing the study, patients were eligible to e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corts-dazucorilant-fails-meet-goal-152100886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0566484027.USD","BK4007","CORT","SPRO","BK4196","CSTL","LU1559883803.SGD","IMCR","BK4505","BK4139","BK4532"],"gpt_icon":0},{"id":"2490499000","title":"AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2490499000","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490499000?lang=en_us&edition=fundamental","pubTime":"2024-12-10 23:39","pubTimestamp":1733845140,"startTime":"0","endTime":"0","summary":"AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-2 study, which evaluated its recently acquired investigational drug tavapadonin adults with early Parkinson’s disease .The study achieved its primary endpoint, as patients who received flexible doses  of once-daily tavapadonfor 26 weeks achieved statistically significant improvement in disease burden. This was measured using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale  Parts II and III combined score, a scale developed to evaluate various aspects of PD.The above results were in line with the positive results from the late-stage TEMPO-1 reported earlier in September that evaluated fixed doses  of once-daily tavapadonfor 26 weeks in adults with early PD. The study achieved its primary endpoint of statistically significant improvement in disease burden.AbbVie intends to use the data from both these studies when it seeks regulatory approval for tavapadonin PD indication next year. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvies-recently-acquired-parkinsons-drug-153900727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2237443549.SGD","IE00BVYPNW00.USD","BK4559","LU2089283258.USD","LU1037948897.HKD","LU0198837287.USD","LU1496350502.SGD","LU0912757837.SGD","LU1169590202.USD","IE00B4R5TH58.HKD","LU1585245621.USD","SPRO","LU1061106388.HKD","PD","BK4196","IE00B2B36J28.USD","LU0795875086.SGD","SG9999015952.SGD","IE00BDGV0183.EUR","LU0170899867.USD","CTMX","ABBV","LU0882574055.USD","BK4588","LU0545039389.USD","LU0114720955.EUR","LU0203347892.USD","LU0985320562.USD","LU1732799900.SGD","SG9999001440.SGD","LU0965509283.SGD","IE0002141913.USD","LU1244550221.USD","BK4533","IE00BFTCPJ56.SGD","SG9999015945.SGD","LU0211328371.USD","IE00BJJMRZ35.SGD","IE00B42XCP33.USD","BK4534","LU1244550577.SGD","LU1291159041.SGD","IE0009355771.USD","LU2237443895.HKD","LU2347655156.SGD","LU1718418525.SGD","BK4139","CSTL","IE00BJT1NW94.SGD","IE0004445239.USD"],"gpt_icon":0},{"id":"2490799937","title":"Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2490799937","media":"Zacks","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490799937?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:23","pubTimestamp":1733750580,"startTime":"0","endTime":"0","summary":"Shares of Beam Therapeutics Inc. BEAM were up 5.5% on Dec. 6 after the company announced that it has appointed Sravan K. Emany as its new chief financial officer .He will assume his new role on Dec. 19, 2024.Emany most recently served as CFO and the chief operating officer at Ironwood Pharmaceuticals. He previously held senior leadership positions at Integra LifeSciences Holdings Corporation, a healthcare company, and also worked as an investment banker at Bank of America and BofA Securities.Emany also held other financial roles at Goldman Sachs and Morgan Stanley and served on the board of directors of Assertio Holdings.BEAM’s erstwhile CFO, Terry-Ann Burrell, stepped down from her role effective Aug. 9, 2024.Beam Therapeutics is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease .Treatment with BEAM-101 also demonstrated rapid neutrophil and platelet engraftment and normalized ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-appoints-sravan-emany-132300768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089283258.USD","BK4504","LU1668664300.SGD","LU0098860793.USD","LU0106261372.USD","LU1162221912.USD","LU1363072403.SGD","BK4505","BK4139","BK4581","LU1989772840.SGD","LU2271345857.HKD","BK4585","BK4556","BK4588","SCD","LU0267386448.USD","LU2111349929.HKD","LU1720051108.HKD","LU1074936037.SGD","IE00BZ1G4Q59.USD","BK4534","LU0971096721.USD","LENZ","BEAM","LU0006306889.USD","LU1720051017.SGD","LU0158827948.USD","LU1989772923.USD","LU2023251221.USD","LU2089284900.SGD","IE00BKVL7J92.USD","BK4535","CSTL","LU0106831901.USD","LU0314104364.USD","BK4196","BK4127","BK4516","CFO","LU0225283273.USD","LU0320765646.SGD","LU1548497426.USD","LU2357305700.SGD","SPRO","LU2028103732.USD","LU0158827781.USD","IMCR"],"gpt_icon":0},{"id":"2489553412","title":"AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2489553412","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489553412?lang=en_us&edition=fundamental","pubTime":"2024-12-06 23:36","pubTimestamp":1733499360,"startTime":"0","endTime":"0","summary":"Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its pipeline candidate, acimtamig .The regulatory body granted the RMAT designation to acimtamig in combination with Artiva Biotherapeutic’s ARTV AlloNK  for the treatment of relapsed or refractory Hodgkin Lymphoma .Despite the FDA’s RMAT designation, shares of Affimed were down 6.5% on Dec. 5 following the announcement of the news. The stock, however, rebounded in after-hour trading and was up 5.6%.The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.Year to date, shares of Affimed have plunged 62.9% compared with the industry’s decline of 8%.In the past 60 days, estimates fo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/afmd-stock-down-despite-fdas-153600588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","ARTV","SPRO","BK4196","AFMD","BK4139"],"gpt_icon":0},{"id":"2489237703","title":"Denali Starts Dosing in Phase II Parkinson's Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2489237703","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489237703?lang=en_us&edition=fundamental","pubTime":"2024-12-06 22:48","pubTimestamp":1733496480,"startTime":"0","endTime":"0","summary":"Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 .BIIB122, an investigational drug leucine-rich repeat kinase 2  inhibitor, is being evaluated in participants with LRRK2-associated Parkinson’s disease .Shares of DNLI have risen 8.7% year to date against the industry’s 8.4% decline.The phase IIa study will evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson’s disease and LRRK2 pathogenic mutations confirmed by genetic testing.In September, Denali announced that its meeting with the FDA's Center for Drug Evaluation and Research  division to advance DNL310 was successful.The meeting with CDER outlined a path for Denali to file a biologics license application  seeking accelerated approval of tividenofusp alfa  for the treatment of MPS II and its subsequent conversion to full approval.Denali agreed with the CDER that cerebrospinal fluid heparan sulfate  is reasonably likely ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/denali-starts-dosing-phase-ii-144800152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z9P08.USD","IE00B894F039.SGD","BK4585","LU0234570918.USD","BK4533","ETV","SPRO","BK4532","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00BFXG1179.USD","BK4007","IE00B19Z9Z06.USD","BIIB","DNLI","BK4535","SNY","BK4588","LU0320765992.SGD","BK4548"],"gpt_icon":1},{"id":"2489491270","title":"GSK Expands Vaccine Collaboration With Zhifei in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2489491270","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489491270?lang=en_us&edition=fundamental","pubTime":"2024-12-06 00:54","pubTimestamp":1733417640,"startTime":"0","endTime":"0","summary":"GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products , China's largest vaccine maker, to co-market its shingles vaccine Shingrix in mainland China.The revised terms extend this deal by an additional eight years to 2034, including revision in expected volumes. GSK expects Zhifei to purchase volumes of Shingrix valued at 2.3 billion  over the 2024-2029 period. Management also stated that the contracted minimum purchase levels specified in the initial agreement are no longer applicable.GSK had initially entered into a collaboration deal, valued at 2.5 billion for three years until 2026, with Zhifei last year to market Shingrix in mainland China. Shingrix is currently approved in China for use in older adults aged 50 years and above.The amended deal also includes exclusive rights for China's largest vaccine company to explore collaboration on GSK's RSV vaccine Arexvy in China for an initial term of 10 years.Year to date, GSK’s shares ha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsk-expands-vaccine-collaboration-zhifei-165400833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GSK.UK","BK4139","BK4532","BK4588","GSK","CSTL","BK4196","BK4585","LU1829250122.USD","SPRO","BK4007"],"gpt_icon":0},{"id":"2489995434","title":"STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489995434","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489995434?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:13","pubTimestamp":1733411580,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Inc. STOK announced that the FDA has granted a Breakthrough Therapy designation to its investigational candidate, zorevunersen , for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.Shares of the company were up 12.1% on Dec. 4 following the announcement of the news.The FDA grants breakthrough therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that the therapy may provide substantial improvements over available treatments.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.Year to date, shares of Stoke Therapeutics have rallied 143.5% against the industry’s decline of 8.3%.In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Loss per share estimates for 2025 hav","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stok-shares-fdas-breakthrough-tag-151300966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","BK4139","STOK","BK4505","BK4196","IMCR","CSTL"],"gpt_icon":0},{"id":"2489493264","title":"AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2489493264","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489493264?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:05","pubTimestamp":1733411100,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN announced that the FDA has approved its blockbuster cancer drug Imfinzi  for treating limited-stage small cell lung cancer  in adult patients whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.Following the latest nod, Imfinzi became the first and only immunotherapy regimen approved for treating LS-SCLC. In August, the FDA accepted and granted a priority review to AZN’s regulatory filing seeking label expansion for Imfinzi in patients with LS-SCLC.The FDA had also granted a breakthrough therapy designation to Imfinzi in this setting.Regulatory applications seeking approval for Imfinzi in LS-SCLC are currently under review in the EU, Japan and several other countries.Year to date, shares of AstraZeneca have decreased 0.9% against the industry’s increase of 9.3%.Latest Approval for Imfinzi Based on AZN's ADRIATIC Study. The approval for the expanded use of Imfinzi was based on data from the phase III ADRIATIC study.Some","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazenecas-imfinzi-gets-fda-nod-150500859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU2417539215.USD","BK4505","BK4139","BK4585","LU0109394709.USD","LU0320765992.SGD","BK4588","AZN","LU2456880835.USD","LU1829250122.USD","CSTL","LU2462157665.USD","BK4196","BK4007","SPRO","LU0889565916.HKD","LU2236285917.USD","IMCR"],"gpt_icon":0},{"id":"2489146614","title":"Cytokinetics Initiates Confirmatory Study on Heart Failure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2489146614","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489146614?lang=en_us&edition=fundamental","pubTime":"2024-12-05 01:30","pubTimestamp":1733333400,"startTime":"0","endTime":"0","summary":"Cytokinetics, Incorporated CYTK announced that the late-stage COMET-HF study on pipeline candidate, omecamtiv mecarbil, has started.COMET-HF  is a confirmatory phase III study of omecamtiv mecarbil in patients with symptomatic heart failure  with severely reduced ejection fraction.Year to date, Cytokinetics’ shares have lost 38.3% compared with the industry’s 8.3% decline.Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator in development for the potential treatment of HF with severely reduced ejection fraction.The phase III COMET-HF study is being conducted in collaboration with Duke Clinical Research Institute, a leading academic research organization. The study is open to enrollment.The multi-center, double-blind, randomized, placebo-controlled study is designed to assess the efficacy and safety of omecamtiv mecarbil in patients with symptomatic HF with severely reduced ejection fraction.Cytokinetics recently announced that the FDA has accepted the compan","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-initiates-confirmatory-study-heart-173000642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","CYTK","BAYRY","SPRO","BK4196","HF","BK4505","BK4588","BK4585","BK4007"],"gpt_icon":0},{"id":"2489167101","title":"JANX Stock Hits Record High on Prostate Cancer Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2489167101","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489167101?lang=en_us&edition=fundamental","pubTime":"2024-12-04 23:04","pubTimestamp":1733324640,"startTime":"0","endTime":"0","summary":"Shares of Janux Therapeutics JANX surged 49% on Tuesday after the company posted updated interim results from a phase Ib study, which is evaluating JANX007 in patients with advanced or metastatic prostate cancer .The study enrolled mCRPC patients who were heavily pretreatedwith a median of four prior lines of therapy. As of the cut-off date of Nov. 15, 2024, 16 patients had been treated with once-weekly JANX007 doses ranging from 2 mg to 9 mg. None of these patients had been treated with Pluvicto, Novartis’ blockbuster prostate cancer therapy.Of the 16 patients, 10 achieved a 90% reduction in PSA levels, with five experiencing a decline of 99%. Management also highlighted the sustained PSA reductions, noting that 75% of patients with a 50% decline maintained it for at least 12 weeks. Similarly, 50% of patients who achieved a 90% PSA decline maintained their reductions for the same duration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/janx-stock-hits-record-high-150400199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4217","BK4585","JANX","BK4533","CSTL","BK4084","BK4196","BK4139","PSA","BK4568","BK4539","VIR","SPRO","BK4535","BK4588"],"gpt_icon":0},{"id":"2488097839","title":"FDA Accepts Cytokinetics' Application for Cardiovascular Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2488097839","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488097839?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:37","pubTimestamp":1733251020,"startTime":"0","endTime":"0","summary":"Cytokinetics, Incorporated CYTK announced that the FDA has accepted the company’s new drug application  for lead pipeline candidate, aficamten.Aficamten is a next-in-class cardiac myosin inhibitor. The NDA is seeking approval of the candidate for the treatment of obstructive hypertrophic cardiomyopathy .Year to date, Cytokinetics’ shares have lost 39.5% compared with the industry’s 7% decline.The NDA is supported by the results from the phase III SEQUOIA-HCM  study on aficamten in patients with symptomatic obstructive HCM.Results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by 1.8 ml/kg/min compared to baseline in patients treated with aficamten versus 0.0 ml/kg/min in patients treated with placebo.Meanwhile, Bayer AG BAYRY will acquire rights to aficamten in Japan. As per the joint development plan, Bayer plans to conduct a phas","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","BK4139","CYTK","BAYRY","SPRO","BK4082","BK4196","BK4505","BK4588","CSII","BK4531","BK4585","HCM","BK4007"],"gpt_icon":0},{"id":"2488507978","title":"PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2488507978","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488507978?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:36","pubTimestamp":1733250960,"startTime":"0","endTime":"0","summary":"Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518, its investigational oral therapy for Huntington's disease .Per the terms of the deal, Novartis will be responsible for developing and marketing PTC518 in HD indication after completion of the ongoing phase II PIVOT-HD study, expected in the first half of next year. PTC Therapeutics will receive an upfront cash payment of $1 billion. The company will also be eligible to receive up to $1.9 billion in milestone payments from Novartis.While both companies will share profits and losses in the United States in the ratio of 40:60 , NVS will be responsible for ex-U.S. sales. PTCT will also be eligible to receive tiered double-digit royalties on ex-U.S. sales of the drug.The deal is expected to be closed in first-quarter 2025, subject to the fulfillment of customary closing conditions, including r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HD","IE00BFTCPJ56.SGD","LU1069344957.HKD","BK4083","BK4121","IE00BJT1NW94.SGD","LU2756315664.SGD","LU0320765646.SGD","LU1093756168.USD","LU0354030511.USD","LU0354030438.USD","CSTL","BK4139","LU1496350171.SGD","BK4581","LU0942090050.USD","LU1551013425.SGD","LU1929549753.HKD","LU1093756325.SGD","LU0820561818.USD","NVS","LU0689472784.USD","BK4196","CRL","IE00B1XK9C88.USD","SG9999001440.SGD","LU0211331839.USD","IE00BSNM7G36.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU1035775433.USD","LU0820562030.AUD","LU0943347566.SGD","SPRO","LU0823434583.USD","IE00BWXC8680.SGD","BK4550","LU0109394709.USD","BK4530","IE00B4R5TH58.HKD","LU0234572021.USD","LU0868494708.USD","PTCT","BK4533","LU1989772923.USD","LU0889565916.HKD","BK4566","LU0823434740.USD","BK4534"],"gpt_icon":0},{"id":"2488792925","title":"SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2488792925","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488792925?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:56","pubTimestamp":1733241360,"startTime":"0","endTime":"0","summary":"Shares of the company skyrocketed 363% on Dec. 2 following the announcement of the news.Per management, a potential first-in-class off-the-shelf CAR-NK cell therapy, SENTI-202, has been developed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, like AML, while not affecting the healthy bone marrow cells.SNTI stock has surged 51.5% so far this year against the industry’s decline of 7.1%.More on the Initial Data from SNTI's Phase I Study. Initial data from the phase I study showed that two out of the three AML patients who were treated at the lowest dose level  achieved complete remission , confirmed by bone marrow biopsy as of the data cutoff date of Sept. 19, 2024.Additionally, both patients achieved measurable residual disease  negative following treatment with SENTI-202.Per the press release, MRD negative indicates that no detectable cancer cells are present in a bone marrow sample as checked by the most sensitive locally available method.Some","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OqpBwYnlazUrZRs4ONCSFw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/snti-stock-skyrockets-initial-data-155600334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRO","IMCR","BK4196","BK4139","CSTL","BK4539","SNTI","BK4505"],"gpt_icon":1},{"id":"2488923995","title":"ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923995","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923995?lang=en_us&edition=fundamental","pubTime":"2024-12-03 23:06","pubTimestamp":1733238360,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions  in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol  and Nexlizet as a treatment to reduce low-density lipoprotein cholesterol or LDL-C  and cardiovascular risk.Nexlizet is a combination of bempedoic acid and ezetimibe.Shares of the company were up 10.7% on Dec. 2 following the announcement of the news.ESPR stock has increased 3.6% so far this year against the industry’s decline of 5.2%.ESPR's Nexletol & Nexlizet Approved in Other Countries. Nexletol and Nexlizet are approved for treating elevated LDL-C and cardiovascular risk reduction in the United States and Europe. The drugs are marketed as Nilemdo and Nustendi in ex-U.S. markets  in partnership with Daiichi Sankyo.In March 2024, the FDA approved label expansions for Nexletol tablets and Nexlizet tablets to include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevent","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.vcXZvNbnFvDkPdENtrKng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.vcXZvNbnFvDkPdENtrKng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/espr-files-drug-submissions-nexletol-150600595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4196","BK4007","CSTL","ESPR","IMCR","SPRO","BK4505"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":103,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"SPRO","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2024-11-14","symbol":"SPRO","fiscalQuarterEnding":"2024/09","expectedEps":-0.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2024-08-05","symbol":"SPRO","fiscalQuarterEnding":"2024/06","expectedEps":-0.35,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":-0.33},{"market":"US","date":"2024-05-15","symbol":"SPRO","fiscalQuarterEnding":"2024/03","expectedEps":-0.07,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-03-13","symbol":"SPRO","fiscalQuarterEnding":"2023/12","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"post","actualEps":0.96}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":3,"updateTime":1743220800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPRO","date":"2025-04-17","current":-0.603309,"percent":0.711601,"low":-57.13681,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"high":18.622772,"avg":-4.181344,"sd":12.508619,"marketCap":41366474},"quantilePoints":[{"date":"2020-04-24","current":-2.869491,"twenty":-5.287923,"median":-4.591235,"eighty":-3.725456,"marketCap":174823724},{"date":"2020-05-01","current":-4.000604,"twenty":-5.286529,"median":-4.581276,"eighty":-3.724053,"marketCap":243736796},{"date":"2020-05-08","current":-3.066735,"twenty":-5.280556,"median":-4.577339,"eighty":-3.724053,"marketCap":242612492},{"date":"2020-05-15","current":-3.105785,"twenty":-5.277465,"median":-4.571125,"eighty":-3.716642,"marketCap":245701785},{"date":"2020-05-22","current":-3.254176,"twenty":-5.271167,"median":-4.561447,"eighty":-3.701399,"marketCap":257441100},{"date":"2020-05-29","current":-3.077149,"twenty":-5.270013,"median":-4.557451,"eighty":-3.646094,"marketCap":243436304},{"date":"2020-06-05","current":-3.238556,"twenty":-5.266561,"median":-4.548464,"eighty":-3.57866,"marketCap":256205382},{"date":"2020-06-12","current":-3.110992,"twenty":-5.261058,"median":-4.534867,"eighty":-3.515876,"marketCap":246113691},{"date":"2020-06-19","current":-3.49108,"twenty":-5.2489,"median":-4.521243,"eighty":-3.49605,"marketCap":276182812},{"date":"2020-06-26","current":-3.425996,"twenty":-5.2489,"median":-4.5202,"eighty":-3.49605,"marketCap":271033990},{"date":"2020-07-02","current":-3.480666,"twenty":-5.240349,"median":-4.516506,"eighty":-3.490924,"marketCap":275359000},{"date":"2020-07-10","current":-3.389549,"twenty":-5.234972,"median":-4.511552,"eighty":-3.490924,"marketCap":268150649},{"date":"2020-07-17","current":-3.474158,"twenty":-5.230001,"median":-4.500168,"eighty":-3.486914,"marketCap":274844118},{"date":"2020-07-24","current":-3.155249,"twenty":-5.217365,"median":-4.491412,"eighty":-3.464005,"marketCap":249614890},{"date":"2020-07-31","current":-3.045909,"twenty":-5.214099,"median":-4.491045,"eighty":-3.447404,"marketCap":240964869},{"date":"2020-08-07","current":-3.289641,"twenty":-5.214007,"median":-4.488361,"eighty":-3.432244,"marketCap":274559982},{"date":"2020-08-14","current":-3.165455,"twenty":-5.210575,"median":-4.476068,"eighty":-3.42079,"marketCap":264195237},{"date":"2020-08-21","current":-3.259228,"twenty":-5.197198,"median":-4.468542,"eighty":-3.398692,"marketCap":272021677},{"date":"2020-08-28","current":-2.663646,"twenty":-5.190349,"median":-4.463316,"eighty":-3.384207,"marketCap":222313205},{"date":"2020-09-04","current":-2.270815,"twenty":-5.189419,"median":-4.454324,"eighty":-3.354954,"marketCap":189526767},{"date":"2020-09-11","current":-3.079737,"twenty":-5.189419,"median":-4.450031,"eighty":-3.345397,"marketCap":257041031},{"date":"2020-09-18","current":-3.141891,"twenty":-5.187231,"median":-4.443879,"eighty":-3.334445,"marketCap":262228539},{"date":"2020-09-25","current":-2.961644,"twenty":-5.183042,"median":-4.402047,"eighty":-3.315755,"marketCap":247184765},{"date":"2020-10-02","current":-3.7526,"twenty":-5.18104,"median":-4.397324,"eighty":-3.31211,"marketCap":313199466},{"date":"2020-10-09","current":-4.141551,"twenty":-5.179836,"median":-4.391541,"eighty":-3.315755,"marketCap":345662097},{"date":"2020-10-16","current":-4.045091,"twenty":-5.177529,"median":-4.357098,"eighty":-3.321863,"marketCap":337611365},{"date":"2020-10-23","current":-4.362475,"twenty":-5.176226,"median":-4.355698,"eighty":-3.325533,"marketCap":364100872},{"date":"2020-10-30","current":-4.079318,"twenty":-5.176016,"median":-4.345999,"eighty":-3.329863,"marketCap":340468076},{"date":"2020-11-06","current":-4.39207,"twenty":-5.1733,"median":-4.347495,"eighty":-3.334445,"marketCap":371924849},{"date":"2020-11-13","current":-4.597547,"twenty":-5.17009,"median":-4.357098,"eighty":-3.338553,"marketCap":389324842},{"date":"2020-11-20","current":-4.873656,"twenty":-5.166153,"median":-4.365586,"eighty":-3.343307,"marketCap":412706083},{"date":"2020-11-27","current":-5.371296,"twenty":-5.16715,"median":-4.391541,"eighty":-3.345335,"marketCap":454846690},{"date":"2020-12-04","current":-5.602457,"twenty":-5.176309,"median":-4.395779,"eighty":-3.345397,"marketCap":474421683},{"date":"2020-12-11","current":-5.522193,"twenty":-5.183953,"median":-4.40059,"eighty":-3.346453,"marketCap":467624810},{"date":"2020-12-18","current":-5.682722,"twenty":-5.192208,"median":-4.4074,"eighty":-3.350803,"marketCap":481218555},{"date":"2020-12-24","current":-7.053638,"twenty":-5.214007,"median":-4.442633,"eighty":-3.354954,"marketCap":597309133},{"date":"2020-12-31","current":-6.225309,"twenty":-5.234162,"median":-4.446594,"eighty":-3.354954,"marketCap":527165411},{"date":"2021-01-08","current":-5.368085,"twenty":-5.261058,"median":-4.450379,"eighty":-3.366119,"marketCap":454574816},{"date":"2021-01-15","current":-5.2814,"twenty":-5.270013,"median":-4.459539,"eighty":-3.373929,"marketCap":447234194},{"date":"2021-01-22","current":-6.032675,"twenty":-5.279365,"median":-4.463316,"eighty":-3.381717,"marketCap":510852918},{"date":"2021-01-29","current":-5.814355,"twenty":-5.288101,"median":-4.468542,"eighty":-3.384207,"marketCap":492365425},{"date":"2021-02-05","current":-6.411523,"twenty":-5.305613,"median":-4.476068,"eighty":-3.385101,"marketCap":542934155},{"date":"2021-02-12","current":-6.533525,"twenty":-5.332316,"median":-4.488361,"eighty":-3.38727,"marketCap":553265401},{"date":"2021-02-19","current":-6.594526,"twenty":-5.345052,"median":-4.491045,"eighty":-3.388835,"marketCap":558431024},{"date":"2021-02-26","current":-5.833619,"twenty":-5.361227,"median":-4.491318,"eighty":-3.396406,"marketCap":493996675},{"date":"2021-03-05","current":-5.246083,"twenty":-5.368258,"median":-4.500168,"eighty":-3.402401,"marketCap":444243570},{"date":"2021-03-12","current":-6.309418,"twenty":-5.371976,"median":-4.50969,"eighty":-3.412251,"marketCap":493901262},{"date":"2021-03-19","current":-5.981509,"twenty":-5.387929,"median":-4.516354,"eighty":-3.419748,"marketCap":468232558},{"date":"2021-03-26","current":-5.205082,"twenty":-5.390332,"median":-4.5202,"eighty":-3.42079,"marketCap":407453789},{"date":"2021-04-01","current":-5.382228,"twenty":-5.390408,"median":-4.521243,"eighty":-3.420837,"marketCap":421320789},{"date":"2021-04-09","current":-4.92994,"twenty":-5.390015,"median":-4.533574,"eighty":-3.422527,"marketCap":385915681},{"date":"2021-04-16","current":-4.873404,"twenty":-5.388431,"median":-4.546657,"eighty":-3.425372,"marketCap":381490043},{"date":"2021-04-23","current":-4.96763,"twenty":-5.385512,"median":-4.556667,"eighty":-3.42912,"marketCap":388866107},{"date":"2021-04-30","current":-5.186236,"twenty":-5.384138,"median":-4.561447,"eighty":-3.434848,"marketCap":405978576},{"date":"2021-05-07","current":-5.34766,"twenty":-5.383374,"median":-4.571125,"eighty":-3.437796,"marketCap":398106514},{"date":"2021-05-14","current":-5.550887,"twenty":-5.383374,"median":-4.577339,"eighty":-3.443639,"marketCap":413235748},{"date":"2021-05-21","current":-5.778023,"twenty":-5.388431,"median":-4.581276,"eighty":-3.449286,"marketCap":430144892},{"date":"2021-05-28","current":-5.778023,"twenty":-5.40792,"median":-4.591235,"eighty":-3.449342,"marketCap":430144892},{"date":"2021-06-04","current":-5.662462,"twenty":-5.417705,"median":-4.597317,"eighty":-3.449426,"marketCap":421541994},{"date":"2021-06-11","current":-6.144628,"twenty":-5.434813,"median":-4.599337,"eighty":-3.453071,"marketCap":457436844},{"date":"2021-06-18","current":-5.845765,"twenty":-5.446368,"median":-4.604387,"eighty":-3.468018,"marketCap":435187970},{"date":"2021-06-25","current":-5.944218,"twenty":-5.457323,"median":-4.615778,"eighty":-3.470102,"marketCap":442517290},{"date":"2021-07-02","current":-6.299275,"twenty":-5.46757,"median":-4.61859,"eighty":-3.472876,"marketCap":468949531},{"date":"2021-07-09","current":-6.287307,"twenty":-5.475294,"median":-4.622569,"eighty":-3.474158,"marketCap":468058556},{"date":"2021-07-16","current":-5.756716,"twenty":-5.489092,"median":-4.626391,"eighty":-3.480666,"marketCap":428558691},{"date":"2021-07-23","current":-5.716821,"twenty":-5.500087,"median":-4.638695,"eighty":-3.480666,"marketCap":425588776},{"date":"2021-07-30","current":-5.32187,"twenty":-5.502843,"median":-4.646898,"eighty":-3.488476,"marketCap":396186620},{"date":"2021-08-06","current":-6.019339,"twenty":-5.513362,"median":-4.65834,"eighty":-3.4903,"marketCap":454556416},{"date":"2021-08-13","current":-5.755408,"twenty":-5.525665,"median":-4.663304,"eighty":-3.4903,"marketCap":434625371},{"date":"2021-08-20","current":-6.581258,"twenty":-5.533309,"median":-4.666253,"eighty":-3.49108,"marketCap":496990254},{"date":"2021-08-27","current":-7.219801,"twenty":-5.546817,"median":-4.67971,"eighty":-3.494402,"marketCap":545210525},{"date":"2021-09-03","current":-7.624212,"twenty":-5.552096,"median":-4.686116,"eighty":-3.49605,"marketCap":575750029},{"date":"2021-09-10","current":-7.798748,"twenty":-5.562419,"median":-4.693364,"eighty":-3.499653,"marketCap":588930237},{"date":"2021-09-17","current":-8.152075,"twenty":-5.582179,"median":-4.697982,"eighty":-3.503388,"marketCap":615612120},{"date":"2021-09-24","current":-7.973283,"twenty":-5.594764,"median":-4.710228,"eighty":-3.509466,"marketCap":602110444},{"date":"2021-10-01","current":-7.470962,"twenty":-5.603316,"median":-4.715815,"eighty":-3.514862,"marketCap":564177164},{"date":"2021-10-08","current":-7.270885,"twenty":-5.619957,"median":-4.72441,"eighty":-3.518383,"marketCap":549068146},{"date":"2021-10-15","current":-7.245343,"twenty":-5.64147,"median":-4.72918,"eighty":-3.521658,"marketCap":547139335},{"date":"2021-10-22","current":-7.177232,"twenty":-5.657325,"median":-4.732389,"eighty":-3.522954,"marketCap":541995840},{"date":"2021-10-29","current":-7.475219,"twenty":-5.670933,"median":-4.736196,"eighty":-3.536236,"marketCap":564498633},{"date":"2021-11-05","current":-7.458191,"twenty":-5.687453,"median":-4.740792,"eighty":-3.542421,"marketCap":563212759},{"date":"2021-11-12","current":-6.86102,"twenty":-5.711236,"median":-4.749034,"eighty":-3.563973,"marketCap":542713529},{"date":"2021-11-19","current":-6.742515,"twenty":-5.718593,"median":-4.751989,"eighty":-3.576764,"marketCap":533339680},{"date":"2021-11-26","current":-6.174509,"twenty":-5.742633,"median":-4.762697,"eighty":-3.582625,"marketCap":488409852},{"date":"2021-12-03","current":-5.541121,"twenty":-5.745538,"median":-4.767707,"eighty":-3.588112,"marketCap":438308246},{"date":"2021-12-10","current":-5.569726,"twenty":-5.747863,"median":-4.770134,"eighty":-3.591569,"marketCap":440570899},{"date":"2021-12-17","current":-5.553381,"twenty":-5.745538,"median":-4.78812,"eighty":-3.601982,"marketCap":439277955},{"date":"2021-12-23","current":-5.729095,"twenty":-5.744668,"median":-4.791373,"eighty":-3.610941,"marketCap":453177110},{"date":"2021-12-31","current":-6.542283,"twenty":-5.752225,"median":-4.794534,"eighty":-3.616718,"marketCap":517501108},{"date":"2022-01-07","current":-5.353148,"twenty":-5.753772,"median":-4.807458,"eighty":-3.62158,"marketCap":423439382},{"date":"2022-01-14","current":-5.394012,"twenty":-5.752225,"median":-4.812969,"eighty":-3.626637,"marketCap":426671744},{"date":"2022-01-21","current":-4.740192,"twenty":-5.749384,"median":-4.815545,"eighty":-3.632464,"marketCap":374953957},{"date":"2022-01-28","current":-4.531787,"twenty":-5.746075,"median":-4.808831,"eighty":-3.647672,"marketCap":358468912},{"date":"2022-02-04","current":-4.343814,"twenty":-5.744835,"median":-4.802417,"eighty":-3.65681,"marketCap":343600048},{"date":"2022-02-11","current":-4.106805,"twenty":-5.743655,"median":-4.792518,"eighty":-3.669066,"marketCap":324852350},{"date":"2022-02-18","current":-3.783981,"twenty":-5.74156,"median":-4.791069,"eighty":-3.673506,"marketCap":299316693},{"date":"2022-02-25","current":-3.873881,"twenty":-5.741354,"median":-4.78527,"eighty":-3.672903,"marketCap":306427889},{"date":"2022-03-04","current":-3.518367,"twenty":-5.741354,"median":-4.7699,"eighty":-3.669563,"marketCap":278306342},{"date":"2022-03-11","current":-3.416208,"twenty":-5.737401,"median":-4.767881,"eighty":-3.646094,"marketCap":270225438},{"date":"2022-03-18","current":-3.42438,"twenty":-5.729095,"median":-4.765727,"eighty":-3.615008,"marketCap":270871910},{"date":"2022-03-25","current":-3.330394,"twenty":-5.720811,"median":-4.751989,"eighty":-3.585269,"marketCap":263437478},{"date":"2022-04-01","current":-2.594724,"twenty":-5.718038,"median":-4.749034,"eighty":-3.543147,"marketCap":232892024},{"date":"2022-04-08","current":-2.685959,"twenty":-5.716835,"median":-4.743166,"eighty":-3.523112,"marketCap":241080914},{"date":"2022-04-14","current":-2.229784,"twenty":-5.716824,"median":-4.739876,"eighty":-3.518367,"marketCap":200136465},{"date":"2022-04-22","current":-1.999871,"twenty":-5.713858,"median":-4.736196,"eighty":-3.503388,"marketCap":179500463},{"date":"2022-04-29","current":-1.773609,"twenty":-5.712894,"median":-4.732389,"eighty":-3.490924,"marketCap":159192016},{"date":"2022-05-06","current":-0.755426,"twenty":-5.711236,"median":-4.72918,"eighty":-3.48159,"marketCap":67804007},{"date":"2022-05-13","current":-0.624047,"twenty":-5.702858,"median":-4.72441,"eighty":-3.473837,"marketCap":56012005},{"date":"2022-05-20","current":-0.439054,"twenty":-5.700864,"median":-4.715815,"eighty":-3.449426,"marketCap":45293730},{"date":"2022-05-27","current":-0.394513,"twenty":-5.699193,"median":-4.710228,"eighty":-3.447094,"marketCap":40698714},{"date":"2022-06-03","current":-0.330882,"twenty":-5.690284,"median":-4.702589,"eighty":-3.433305,"marketCap":34134405},{"date":"2022-06-10","current":-0.340426,"twenty":-5.683482,"median":-4.696894,"eighty":-3.422991,"marketCap":35119052},{"date":"2022-06-17","current":-0.298366,"twenty":-5.682255,"median":-4.689296,"eighty":-3.417395,"marketCap":30780043},{"date":"2022-06-24","current":-0.299066,"twenty":-5.678341,"median":-4.684128,"eighty":-3.397857,"marketCap":30852251},{"date":"2022-07-01","current":-0.263242,"twenty":-5.671936,"median":-4.673321,"eighty":-3.386215,"marketCap":27156545},{"date":"2022-07-08","current":-0.262351,"twenty":-5.670421,"median":-4.665101,"eighty":-3.380277,"marketCap":27064645},{"date":"2022-07-15","current":-0.251343,"twenty":-5.668792,"median":-4.662662,"eighty":-3.355763,"marketCap":25929019},{"date":"2022-07-22","current":-0.239603,"twenty":-5.661665,"median":-4.658465,"eighty":-3.345397,"marketCap":24717904},{"date":"2022-07-29","current":-0.232953,"twenty":-5.658189,"median":-4.649834,"eighty":-3.332999,"marketCap":24031934},{"date":"2022-08-05","current":-0.271941,"twenty":-5.656983,"median":-4.638695,"eighty":-3.324822,"marketCap":28053981},{"date":"2022-08-12","current":-0.241477,"twenty":-5.656009,"median":-4.630492,"eighty":-3.298983,"marketCap":27352632},{"date":"2022-08-19","current":-0.304169,"twenty":-5.651859,"median":-4.622849,"eighty":-3.28605,"marketCap":34453796},{"date":"2022-08-26","current":-0.28064,"twenty":-5.646896,"median":-4.61859,"eighty":-3.259567,"marketCap":31788667},{"date":"2022-09-02","current":-0.224976,"twenty":-5.644127,"median":-4.615778,"eighty":-3.246458,"marketCap":25483535},{"date":"2022-09-09","current":-0.346737,"twenty":-5.640585,"median":-4.6058,"eighty":-3.222936,"marketCap":39275574},{"date":"2022-09-16","current":-0.278628,"twenty":-5.637707,"median":-4.599337,"eighty":-3.215126,"marketCap":31560729},{"date":"2022-09-23","current":-0.609885,"twenty":-5.631352,"median":-4.597547,"eighty":-3.190148,"marketCap":69082929},{"date":"2022-09-30","current":-0.619173,"twenty":-5.622753,"median":-4.591235,"eighty":-3.174978,"marketCap":70134954},{"date":"2022-10-07","current":-0.578927,"twenty":-5.619258,"median":-4.581276,"eighty":-3.159693,"marketCap":65576181},{"date":"2022-10-14","current":-0.612981,"twenty":-5.617086,"median":-4.577339,"eighty":-3.153712,"marketCap":69433604},{"date":"2022-10-21","current":-0.585118,"twenty":-5.607799,"median":-4.571125,"eighty":-3.144373,"marketCap":66277531},{"date":"2022-10-28","current":-0.609885,"twenty":-5.605826,"median":-4.563951,"eighty":-3.129215,"marketCap":69082929},{"date":"2022-11-04","current":-0.585118,"twenty":-5.602689,"median":-4.558235,"eighty":-3.117302,"marketCap":66277531},{"date":"2022-11-11","current":-0.750715,"twenty":-5.602457,"median":-4.550515,"eighty":-3.107707,"marketCap":85034954},{"date":"2022-11-18","current":-0.94528,"twenty":-5.602457,"median":-4.53616,"eighty":-3.104599,"marketCap":96821219},{"date":"2022-11-25","current":-0.970555,"twenty":-5.599889,"median":-4.531787,"eighty":-3.094731,"marketCap":99410021},{"date":"2022-12-02","current":-0.970555,"twenty":-5.598514,"median":-4.521243,"eighty":-3.082423,"marketCap":99410021},{"date":"2022-12-09","current":-0.88462,"twenty":-5.594581,"median":-4.519318,"eighty":-3.068818,"marketCap":90608092},{"date":"2022-12-16","current":-0.849235,"twenty":-5.593249,"median":-4.516004,"eighty":-3.045488,"marketCap":86983769},{"date":"2022-12-23","current":-0.80374,"twenty":-5.590343,"median":-4.507828,"eighty":-3.001981,"marketCap":82323924},{"date":"2022-12-30","current":-0.87451,"twenty":-5.587699,"median":-4.500168,"eighty":-2.925595,"marketCap":89572571},{"date":"2023-01-06","current":-0.909895,"twenty":-5.587699,"median":-4.491045,"eighty":-2.881897,"marketCap":93196895},{"date":"2023-01-13","current":-1.010994,"twenty":-5.587699,"median":-4.477497,"eighty":-2.7929,"marketCap":103552106},{"date":"2023-01-20","current":-0.950335,"twenty":-5.587699,"median":-4.466436,"eighty":-2.732909,"marketCap":97338979},{"date":"2023-01-27","current":-0.920005,"twenty":-5.587699,"median":-4.454324,"eighty":-2.67399,"marketCap":94232416},{"date":"2023-02-03","current":-0.960445,"twenty":-5.583235,"median":-4.443439,"eighty":-2.641266,"marketCap":98374500},{"date":"2023-02-10","current":-0.90484,"twenty":-5.583235,"median":-4.402047,"eighty":-2.609436,"marketCap":92679134},{"date":"2023-02-17","current":-0.8644,"twenty":-5.583235,"median":-4.39207,"eighty":-2.581469,"marketCap":88537050},{"date":"2023-02-24","current":-0.763301,"twenty":-5.583235,"median":-4.365586,"eighty":-2.554574,"marketCap":78181840},{"date":"2023-03-03","current":-0.753191,"twenty":-5.583235,"median":-4.351987,"eighty":-2.49002,"marketCap":77146318},{"date":"2023-03-10","current":-0.748136,"twenty":-5.583235,"median":-4.340393,"eighty":-2.435794,"marketCap":76628558},{"date":"2023-03-17","current":-0.687476,"twenty":-5.569418,"median":-4.315732,"eighty":-2.391745,"marketCap":70415432},{"date":"2023-03-24","current":-0.722861,"twenty":-5.553381,"median":-4.306481,"eighty":-2.317441,"marketCap":74039755},{"date":"2023-03-31","current":-1.642338,"twenty":-5.547029,"median":-4.288241,"eighty":-2.269765,"marketCap":76229128},{"date":"2023-04-06","current":-1.642338,"twenty":-5.547029,"median":-4.263777,"eighty":-2.208281,"marketCap":76229128},{"date":"2023-04-14","current":-1.936826,"twenty":-5.538381,"median":-4.208866,"eighty":-2.122491,"marketCap":89897800},{"date":"2023-04-21","current":-1.902847,"twenty":-5.538381,"median":-4.199845,"eighty":-1.995117,"marketCap":88320645},{"date":"2023-04-28","current":-2.016112,"twenty":-5.538381,"median":-4.167033,"eighty":-1.97096,"marketCap":93577827},{"date":"2023-05-05","current":-2.129376,"twenty":-5.538381,"median":-4.134222,"eighty":-1.959479,"marketCap":98835008},{"date":"2023-05-12","current":-2.174682,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":100937880},{"date":"2023-05-19","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-05-26","current":-3.426213,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":92000672},{"date":"2023-06-02","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-09","current":-3.524105,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":94629263},{"date":"2023-06-16","current":-3.073803,"twenty":-5.538381,"median":-4.110891,"eighty":-1.959479,"marketCap":82537746},{"date":"2023-06-23","current":-2.878019,"twenty":-5.538748,"median":-4.106805,"eighty":-1.959479,"marketCap":77280565},{"date":"2023-06-30","current":-2.780127,"twenty":-5.538932,"median":-4.088313,"eighty":-1.959479,"marketCap":74651974},{"date":"2023-07-07","current":-2.799705,"twenty":-5.535376,"median":-4.066769,"eighty":-1.959479,"marketCap":75177692},{"date":"2023-07-14","current":-2.975911,"twenty":-5.533309,"median":-4.057057,"eighty":-1.959479,"marketCap":79909155},{"date":"2023-07-21","current":-2.858441,"twenty":-5.533309,"median":-4.0428,"eighty":-1.959479,"marketCap":76754846},{"date":"2023-07-28","current":-2.721392,"twenty":-5.533309,"median":-4.025839,"eighty":-1.959479,"marketCap":73074820},{"date":"2023-08-04","current":-2.956332,"twenty":-5.533309,"median":-4.014818,"eighty":-1.959479,"marketCap":79383437},{"date":"2023-08-11","current":-7.559414,"twenty":-5.535376,"median":-4.006786,"eighty":-1.959479,"marketCap":76229128},{"date":"2023-08-18","current":-6.976353,"twenty":-5.547877,"median":-4.006786,"eighty":-1.959479,"marketCap":70349545},{"date":"2023-08-25","current":-6.796031,"twenty":-5.557245,"median":-4.006786,"eighty":-1.959479,"marketCap":68531175},{"date":"2023-09-01","current":-7.841574,"twenty":-5.577899,"median":-4.006786,"eighty":-1.959479,"marketCap":79074433},{"date":"2023-09-08","current":-7.00514,"twenty":-5.590343,"median":-4.006107,"eighty":-1.957214,"marketCap":70639827},{"date":"2023-09-15","current":-6.743754,"twenty":-5.600531,"median":-4.008698,"eighty":-1.954949,"marketCap":68004012},{"date":"2023-09-22","current":-6.377814,"twenty":-5.619353,"median":-4.008698,"eighty":-1.954949,"marketCap":64313872},{"date":"2023-09-27","current":-6.325536,"twenty":-5.635165,"median":-4.007465,"eighty":-1.952683,"marketCap":63786709},{"date":"2023-10-06","current":-6.064151,"twenty":-5.656766,"median":-4.006107,"eighty":-1.948153,"marketCap":61150895},{"date":"2023-10-13","current":-5.855042,"twenty":-5.670432,"median":-4.007465,"eighty":-1.948153,"marketCap":59042243},{"date":"2023-10-20","current":-5.724349,"twenty":-5.700864,"median":-4.017086,"eighty":-1.948153,"marketCap":57724336},{"date":"2023-10-27","current":-5.227716,"twenty":-5.700864,"median":-4.025257,"eighty":-1.940491,"marketCap":52716289},{"date":"2023-11-03","current":-5.959596,"twenty":-5.712838,"median":-4.040427,"eighty":-1.938575,"marketCap":60096569},{"date":"2023-11-10","current":-5.489102,"twenty":-5.718038,"median":-4.056342,"eighty":-1.938575,"marketCap":55352103},{"date":"2023-11-17","current":-38.091206,"twenty":-5.738192,"median":-4.064,"eighty":-1.938225,"marketCap":61479207},{"date":"2023-11-24","current":-39.076324,"twenty":-5.745362,"median":-4.0782,"eighty":-1.938225,"marketCap":63069187},{"date":"2023-12-01","current":-37.434462,"twenty":-5.756595,"median":-4.110221,"eighty":-1.938225,"marketCap":60419221},{"date":"2023-12-08","current":-41.374931,"twenty":-5.775828,"median":-4.143107,"eighty":-1.938575,"marketCap":66779139},{"date":"2023-12-15","current":-42.688421,"twenty":-5.801932,"median":-4.180228,"eighty":-1.938575,"marketCap":68899112},{"date":"2023-12-22","current":-44.658656,"twenty":-5.81944,"median":-4.20788,"eighty":-1.938575,"marketCap":72079071},{"date":"2023-12-29","current":-47.94238,"twenty":-5.826574,"median":-4.262087,"eighty":-1.938225,"marketCap":77379002},{"date":"2024-01-05","current":-48.270753,"twenty":-5.837472,"median":-4.288241,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-01-12","current":-47.94238,"twenty":-5.855042,"median":-4.312399,"eighty":-1.937875,"marketCap":77379002},{"date":"2024-01-19","current":-46.300518,"twenty":-5.879021,"median":-4.328063,"eighty":-1.937526,"marketCap":74729036},{"date":"2024-01-26","current":-51.226105,"twenty":-5.88973,"median":-4.348245,"eighty":-1.937875,"marketCap":82678934},{"date":"2024-02-02","current":-51.554478,"twenty":-5.907523,"median":-4.3779,"eighty":-1.937875,"marketCap":83208927},{"date":"2024-02-09","current":-44.330283,"twenty":-5.93365,"median":-4.402487,"eighty":-1.937875,"marketCap":71549077},{"date":"2024-02-16","current":-49.912615,"twenty":-5.959596,"median":-4.448819,"eighty":-1.937875,"marketCap":80558961},{"date":"2024-02-23","current":-48.270753,"twenty":-5.960111,"median":-4.478613,"eighty":-1.937875,"marketCap":77908995},{"date":"2024-03-01","current":-54.181458,"twenty":-5.982254,"median":-4.491224,"eighty":-1.938225,"marketCap":87448873},{"date":"2024-03-08","current":-56.808437,"twenty":-6.011873,"median":-4.516354,"eighty":-1.938225,"marketCap":91688818},{"date":"2024-03-15","current":4.043621,"twenty":-6.022006,"median":-4.491224,"eighty":-1.934561,"marketCap":92218811},{"date":"2024-03-22","current":4.086364,"twenty":-6.022006,"median":-4.443439,"eighty":-1.853014,"marketCap":93193610},{"date":"2024-03-28","current":4.133605,"twenty":-6.022006,"median":-4.402047,"eighty":-1.811563,"marketCap":94270993},{"date":"2024-04-05","current":3.991881,"twenty":-6.024673,"median":-4.364031,"eighty":-1.717093,"marketCap":91038844},{"date":"2024-04-12","current":4.039122,"twenty":-6.024673,"median":-4.337431,"eighty":-1.389071,"marketCap":92116227},{"date":"2024-04-19","current":3.473759,"twenty":-6.024673,"median":-4.314454,"eighty":-0.978642,"marketCap":79222546},{"date":"2024-04-26","current":3.379235,"twenty":-6.022006,"median":-4.28696,"eighty":-0.969544,"marketCap":77066831},{"date":"2024-05-03","current":3.804593,"twenty":-6.022006,"median":-4.217087,"eighty":-0.959434,"marketCap":86767551},{"date":"2024-05-10","current":3.993641,"twenty":-6.022006,"median":-4.1681,"eighty":-0.950335,"marketCap":91078982},{"date":"2024-05-17","current":3.615427,"twenty":-6.011873,"median":-4.125993,"eighty":-0.940225,"marketCap":84611835},{"date":"2024-05-24","current":3.408173,"twenty":-6.011873,"median":-4.106805,"eighty":-0.93517,"marketCap":79761475},{"date":"2024-05-31","current":3.275692,"twenty":-6.011873,"median":-4.076207,"eighty":-0.930115,"marketCap":76661027},{"date":"2024-06-07","current":3.344897,"twenty":-6.011873,"median":-4.057326,"eighty":-0.924049,"marketCap":78280626},{"date":"2024-06-14","current":3.160351,"twenty":-6.011873,"median":-4.040427,"eighty":-0.90484,"marketCap":73961695},{"date":"2024-06-21","current":3.068078,"twenty":-6.003499,"median":-4.018913,"eighty":-0.896752,"marketCap":71802229},{"date":"2024-06-28","current":3.091146,"twenty":-5.980399,"median":-4.012297,"eighty":-0.878554,"marketCap":72342096},{"date":"2024-07-05","current":3.056544,"twenty":-5.980399,"median":-4.001489,"eighty":-0.868444,"marketCap":71532296},{"date":"2024-07-12","current":3.194953,"twenty":-5.980399,"median":-3.95478,"eighty":-0.853279,"marketCap":74771495},{"date":"2024-07-15","current":3.264158,"twenty":-5.980399,"median":-3.952342,"eighty":-0.847213,"marketCap":76391094},{"date":"2024-08-02","current":3.206488,"twenty":-5.989796,"median":-3.8984,"eighty":-0.814861,"marketCap":75041428},{"date":"2024-08-09","current":3.901571,"twenty":-5.989796,"median":-3.877968,"eighty":-0.80374,"marketCap":68101915},{"date":"2024-08-16","current":3.746746,"twenty":-5.989796,"median":-3.861795,"eighty":-0.763301,"marketCap":65399458},{"date":"2024-08-23","current":4.180254,"twenty":-5.989796,"median":-3.820123,"eighty":-0.75121,"marketCap":72966337},{"date":"2024-08-30","current":4.242184,"twenty":-5.989796,"median":-3.788068,"eighty":-0.744092,"marketCap":74047320},{"date":"2024-09-06","current":4.118324,"twenty":-5.989796,"median":-3.774547,"eighty":-0.731947,"marketCap":71885354},{"date":"2024-09-13","current":4.118324,"twenty":-5.989796,"median":-3.739031,"eighty":-0.708707,"marketCap":71885354},{"date":"2024-09-20","current":4.195737,"twenty":-5.989796,"median":-3.720328,"eighty":-0.687476,"marketCap":73236583},{"date":"2024-09-27","current":3.9635,"twenty":-5.989796,"median":-3.691537,"eighty":-0.654404,"marketCap":69182897},{"date":"2024-10-04","current":3.994465,"twenty":-5.989796,"median":-3.653986,"eighty":-0.635451,"marketCap":69723389},{"date":"2024-10-11","current":3.839641,"twenty":-5.989796,"median":-3.621997,"eighty":-0.621128,"marketCap":67020932},{"date":"2024-10-18","current":3.978983,"twenty":-5.989796,"median":-3.56918,"eighty":-0.619173,"marketCap":69453143},{"date":"2024-10-25","current":3.901571,"twenty":-5.989796,"median":-3.534712,"eighty":-0.609885,"marketCap":68101915},{"date":"2024-10-31","current":3.994465,"twenty":-5.989796,"median":-3.524105,"eighty":-0.607408,"marketCap":69723389},{"date":"2024-11-08","current":4.056395,"twenty":-5.990937,"median":-3.497588,"eighty":-0.594406,"marketCap":70804372},{"date":"2024-11-15","current":3.870606,"twenty":-5.990937,"median":-3.48159,"eighty":-0.578927,"marketCap":67561423},{"date":"2024-11-22","current":18.467582,"twenty":-5.990937,"median":-3.470102,"eighty":-0.458144,"marketCap":64876616},{"date":"2024-11-29","current":17.691633,"twenty":-5.990937,"median":-3.457398,"eighty":-0.423147,"marketCap":62150708},{"date":"2024-12-06","current":18.002013,"twenty":-5.990937,"median":-3.43318,"eighty":-0.381786,"marketCap":63241071},{"date":"2024-12-13","current":17.070874,"twenty":-5.990937,"median":-3.422585,"eighty":-0.359516,"marketCap":59969981},{"date":"2024-12-20","current":15.487939,"twenty":-5.990937,"median":-3.404992,"eighty":-0.334353,"marketCap":54409128},{"date":"2024-12-27","current":14.648362,"twenty":-5.990937,"median":-3.386446,"eighty":-0.330882,"marketCap":51459695},{"date":"2025-01-03","current":16.760495,"twenty":-5.990937,"median":-3.370704,"eighty":-0.318874,"marketCap":58879618},{"date":"2025-01-10","current":15.518977,"twenty":-5.995124,"median":-3.345397,"eighty":-0.303395,"marketCap":54518165},{"date":"2025-01-17","current":12.956793,"twenty":-5.995124,"median":-3.326307,"eighty":-0.29671,"marketCap":45517215},{"date":"2025-01-24","current":13.513925,"twenty":-5.995124,"median":-3.295829,"eighty":-0.285503,"marketCap":47474418},{"date":"2025-01-31","current":13.50151,"twenty":-5.995124,"median":-3.259228,"eighty":-0.278399,"marketCap":47430803},{"date":"2025-02-07","current":13.397532,"twenty":-5.995124,"median":-3.238556,"eighty":-0.271439,"marketCap":47065531},{"date":"2025-02-14","current":12.674348,"twenty":-5.995124,"median":-3.20854,"eighty":-0.261142,"marketCap":44524985},{"date":"2025-02-21","current":12.984728,"twenty":-5.995124,"median":-3.176076,"eighty":-0.253659,"marketCap":45615348},{"date":"2025-02-28","current":12.10325,"twenty":-5.995124,"median":-3.155249,"eighty":-0.248371,"marketCap":42518716},{"date":"2025-03-07","current":12.228954,"twenty":-5.999311,"median":-3.12706,"eighty":-0.245393,"marketCap":42960314},{"date":"2025-03-14","current":12.081523,"twenty":-5.999311,"median":-3.115449,"eighty":-0.2427,"marketCap":42442391},{"date":"2025-03-21","current":12.067556,"twenty":-5.999311,"median":-3.115449,"eighty":-0.238173,"marketCap":42393325},{"date":"2025-03-28","current":13.347872,"twenty":-5.999311,"median":-3.115449,"eighty":-0.222173,"marketCap":46891073},{"date":"2025-04-04","current":-0.508736,"twenty":-5.999311,"median":-3.115449,"eighty":-0.222173,"marketCap":34881999},{"date":"2025-04-11","current":-0.470825,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"marketCap":32282620},{"date":"2025-04-17","current":-0.603309,"twenty":-5.995124,"median":-3.113595,"eighty":-0.223574,"marketCap":41366474}],"updateTime":1745143798892}}}